Annie Li: Monitoring Sarcomas with Novel Radiation Sparing Technologies

This event is eligible for EACCME® accreditation.

• Join the Pro Learning Circle to access CME benefits and qualify for credit.

• After attending the full live event and completing the required activities, claim your CME credits here.

www.surgeon-events.org

The landscape of tumor monitoring is changing, and Dr. Li’s work in sarcomas is a perfect example of this revolutionary shift. Her work is setting the

→ Need more details? Visit our Accreditation Information page.

The landscape of tumor monitoring is changing, and Dr. Li’s work in sarcomas is a perfect example of this revolutionary shift. By using liquid biopsies to detect EWSR1 gene fusions in cell-free DNA, Dr. Li offers a precise, non-invasive method for tracking sarcoma progression—without the risks associated with repeated radiation exposure.

This technique allows for personalized monitoring, identifying unique fusion breakpoints in each patient and creating customized assays for real-time tumor tracking. It’s a breakthrough aligned with the principles of precision medicine, where treatment and monitoring are tailored to the individual.

Surgeons need to understand that this is more than just a technological advancement; it’s a paradigm shift in how we approach tumor management. By reducing reliance on traditional imaging, this method not only enhances monitoring accuracy but also improves long-term patient care. Dr. Li’s work is setting the stage for a new standard in cancer monitoring, and it’s one we all need to pay attention to.

LEARNING OBJECTIVES:

By the end of this lecture, participants will be able to:

• Describe the challenges of detecting EWSR1 gene fusions in plasma cfDNA, including structural complexity and patient-specific intronic breakpoints.

• Explain how liquid biopsy approaches, including cfDNA analysis, can provide a non-invasive alternative for tracking tumor burden.

• Discuss the development and application of personalized assays targeting patient-specific EWSR1 fusion breakpoints.

• Evaluate the potential of integrating radiation-sparing liquid biopsy strategies into longitudinal disease monitoring and clinical decision-making for sarcoma patients.

TARGET AUDIENCE

• Medical Oncologists

• Surgical Oncologists

• Pediatric Oncologists

• Sarcoma Specialists

• Molecular Pathologists and Laboratory Medicine Specialists

• Oncology Nurses and Allied Health Professionals

• Clinical Researchers in Molecular Diagnostics and Cancer Biomarkers

• Residents and Fellows in Oncology, Pathology, and Related Disciplines

SPEAKER: Annie Li, MD, Post-Doctoral Research Fellow, MGH Pathology, Harvard Medical School 

ONLINE LIVE EVENT (Free of Charge)

San Francisco: Monday, October 27, 2025 at 4:00 pm

Mexico City: Monday, October 27, 2025 at 5:00 pm

New York: Monday, October 27, 2025 at 7:00 pm

Rio de Janeiro: Monday, October 27, 2025 at 8:00 pm

London: Monday, October 27, 2025 at 11:00 pm

Berlin: Tuesday, October 28, 2025 at 12:00 midnight

Johannesburg: Tuesday, October 28, 2025 at 1:00 am

Cairo: Tuesday, October 28, 2025 at 2:00 am

Dubai: Tuesday, October 28, 2025 at 3:00 am

Delhi: Tuesday, October 28, 2025 at 4:30 am

Manila: Tuesday, October 28, 2025 at 7:00 am

Sydney: Tuesday, October 28, 2025 at 10:00 am

LANGUAGE: The event language is english. 

DECLARATION: In accordance with criterion 13 of document UEMS 2023.07.rev “EACCME® Criteria for the Accreditation of Live Educational Events (LEEs)” and the Standard v. Commercial or Promotional Conflict of Interest, published by the American Dental Association Continuing Education Recognition Program (ADA CERP), all surgeON presenters sign a Conflict of Interest form to document all perceived or actual conflicts of interest for the last 3 years, whether due to a financial or other relationship. This document can be viewed at the beginning of the event or on request by emailing info@surgeon-events.org No fee, honorarium or arrangement for re-imbursement of expenses in relation to the this event has been provided to the speaker.